Partner with Us

Tap in to the #1 research intensive hospital in Canada.

SickKids innovators are at the forefront of pediatric health. The business development team at Industry Partnerships and Commercialization (IP&C) connects investors and industry partners with our researchers, providing access to the cutting-edge SickKids innovation ecosystem.

SickKids Researcher Adam Shlien sits beside a colleague in a research office, working on a presentation

Licensing Opportunities

Browse over 100 technologies available for licensing or further development across IP&C’s technology portfolio.

A SickKids researcher pipettes into a gel electrophoresis plate

Start-Up Potential

Help facilitate the creation and development of start-up companies founded on SickKids innovation.

Areas of Expertise

IP&C maintains an extensive intellectual property portfolio with numerous research and clinical inventions available for licensing and development. These technologies span various areas of excellence at SickKids and align with top market opportunities, including:

Anti-Infectives
Cardiovascular
Cystic Fibrosis
Developmental disorders
Diagnostics
Gene editing
Immunology
Medical devices
Neuromuscular disorders
Orphan and rare diseases
Paediatric oncology
Stem cells and regenerative medicine

SickKids Start-Ups

IP&C helps SickKids innovators turn breakthrough research innovation into companies with real impact.

History of Innovation at SickKids

From the invention of Pablum to the discovery of the cystic fibrosis gene, SickKids innovators have consistently pushed the boundaries of medicine to improve patient lives in Canada and worldwide. Join the legacy of innovation at SickKids by partnering with IP&C.

1930

Invented Pablum, the first ready-to-use enriched baby cereal that saved thousands of children from death and disease

1963

Developed the Mustard surgical procedure to help correct heart problems in blue baby syndrome

1989

Discovered the Cystic Fibrosis gene, paving the path for individualized medicine

1993

Discovered the Wilson disease gene, allowing for better diagnosis and treatment of liver disease

2004

Discovered the phenomena of copy number variation (CNVs)

2010

Co-developed the Hemophilia Joint Health Score (HJHS) as a validated multi-item outcome measure for the assessment of joint health primarily designed for children with hemophilia aged 4 to 18 years old with mild joint impairment (e.g., treated with prophylaxis)

2017

Co-developed the Pediatric Ulcerative Colitis Activity Index (PUCAI) as a validated multi-item outcome measure of ulcerative colitis disease activity that meets the need for non-invasive testing of paediatric patients with ulcerative colitis

2019

Appointed first-ever Chair in Biomedical Informatics and Artificial Intelligence, the first of its kind at a Canadian children’s hospital